Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
SYNERGY-NASH: Tirzepatide and metabolic steatohepatitis (MASH) SYNERGY-NASH (Loomba et al., NEJM 2024, NEJMoa2401943, PMID 38856224) is a phase 2 trial in 190 patients with metabolic steatohepatitis (MASH) and biopsy-proven stage 2 or 3 fibrosis
Semaglutide is an FDA-approved GLP-1 receptor agonist for weight management, backed by the large STEP trial program
The capsule formulation guarantees the integrity of the active ingredient
Join our fight to protect Medicare AARP is working to keep Medicare strong
US$ 24.29
US$ 21.41
US$ 29.50
US$ 22.51
US$ 24.73
US$ 28.61
US$ 23.26
US$ 26.21
US$ 23.82
US$ 22.79
US$ 21.93
